Nichole Tucker, MA, is the Senior Editor for Targeted Oncology and host of the Targeted Talks podcast. Tucker received her Bachelor of Arts in Mass Communications from Virginia State University and her Master of Arts in Media & International Conflict from University College Dublin.
A New Framework Addresses Ethical Concerns With the Use of Biopsies in Clinical TrialsAugust 7th 2019
Mark J. Ratain, MD provided guidance on the current landscape for research biopsies in clinical trials and talked through the recommendations and how the new ethical framework can improve clinical trials during an interview with <em>Targeted Oncology</em>. He also explained the potential role for liquid biopsies and blood-based biomarker testing within clinical research.
MRD Reported Undetectable After Liso-cel CAR T-cell Therapy in CLLAugust 2nd 2019
In the phase I/II TRANSCEND CLL 004 study, chimeric antigen receptor T-cell therapy lisocabtagene maraleucel led to undetectable minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia.
ctDNA Testing Beneficial For Lymphoma Management During Multiple Stages of TreatmentAugust 2nd 2019
In an interview with <em>Targeted Oncology</em>, Kieron Dunleavy, MD, examined the role of liquid biopsy throughout the course of disease for all lymphomas, and specifically for patients with mantle cell lymphoma, and how its role may change in the future.
Assessing the Role CAR T-cell Therapy Plays in Mantle Cell Lymphoma Treatment in ZUMA-2 TrialJuly 31st 2019
Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with <em>Targeted Oncology</em>.
Liquid Biopsies and Next-Generation Sequencing Advance Precision Medicine in HR+ Breast CancerJuly 31st 2019
During an interview with <em>Targeted Oncology</em>, Aditya Bardia, MD, MPH, discussed the current role of both liquid biopsy and NGS in breast cancer management, improvements that are needed, and research that shows a promising future.
Frontline Therapy for Mantle Cell Lymphoma Should Be Individualized Expert UrgesJuly 24th 2019
In an interview with <em>Targeted Oncology</em>, Peter Martin, MD, assistant professor of medicine, Division of Hematology/Oncology, Weil Cornell Medicine, recounts physician crossfire discussions related to frontline MCL treatment and provides his own expert opinion on the subject.
Sonpavde Provides Overview of New Research That Advances Urothelial Cancer TreatmentsJuly 24th 2019
During an interview with <em>Targeted Oncology</em>, Guru P. Sonpavde, MD highlights the extensive research around checkpoint inhibition and chemotherapy combinations and how these regimens are advancing bladder cancer treatment.
Advancements in Frontline AML Treatment Could Lead to Better Patient OutcomesJuly 23rd 2019
Over the past 2 years, the amount of FDA-approved frontline treatments for patients with acute myeloid leukemia have increased. These emergent treatments have caused a shift in the standard of care for patients with AML and inspiring analyses of regimens that researchers believe can improve outcomes for AML treatment.
Improved Overall Survival in mHSPC With Enzalutamide Plus Standard of CareJuly 18th 2019
Testosterone suppression with docetaxel, the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC), was combined with chemotherapy or enzalutamide (Xtandi) to assess the potential improvement in overall survival compared with non-steroidal anti-androgens like bicalutamide, nilutamide, and flutamide in the phase III ENZAMET trial. <br />
Erlotinib Plus Ramucirumab Considered a New Option for Treating EGFR+ Metastatic NSCLCJuly 16th 2019
The combination of erlotinib and ramucirumab showed better progression-free survival in patients with newly diagnosed <em>EGFR</em>-mutant metastatic non–small cell lung cancer compared with erlotinib plus placebo, based on findings from the RELAY trial presented during the 2019 ASCO Annual Meeting.
Zanubrutinib Confirmed Highly Active for Relapsed/Refractory MCLJuly 16th 2019
A single-arm, multicenter phase II trial held in China analyzed the Bruton’s tyrosine kinase inhibitor zanubrutinib for treatment of patients with relapsed/refractory mantle cell lymphoma. Previously, the investigational BTK inhibitor gained a breakthrough designation from the FDA based on early results from the phase II trial that showed zanubrutinib to be highly active.<br />
ACCC Collaborates to Launch Care Improvement Initiative for Patients With Ovarian CancerJuly 12th 2019
The Association of Community Cancer Centers has launched the Barriers to Quality Care in Ovarian Cancer project, a collaboration with AstraZeneca, Merck, and partners including the Association for Molecular Pathology, the National Society of Genetic Counselors, and the Society of Gynecologic Oncology. The project aims to understand the key issues associated with ovarian cancer care and provide guidance to help cancer centers implement better care for patients diagnosed with epithelial ovarian cancer.
Pembrolizumab for cSCC Testing Against Placebo In KEYNOTE-630 TrialJuly 10th 2019
In an interview with <em>Targeted Oncology</em>, Shlomo Koyfman, MD, the director of head and neck and skin cancer radiation at Cleveland Clinic, provides details about the current treatments for cSCC and how the new KEYNOTE-630 trial could improve practice for oncologists who treat cSCC.
Liquid Biopsy Complements Tissue Biopsy In NSCLC ManagementJuly 3rd 2019
A new study shows comparability between liquid biopsy and tissue biopsy in both diagnostics and monitoring of non–small cell lung cancer (NSCLC). However, based on the results, liquid biopsies may be preferable to help oncologists make swifter decisions that help manage the disease.<br />
Regorafenib Plus Nivolumab Limits Tumor Growth In Gastric and Colorectal CancersJuly 2nd 2019
In an interview with <em>Targeted Oncology</em>, Shota Fukuoka, MD, PhD, of the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, commented on the results of the study and the future plans to expand the research with a larger cohort.
Turk Discusses Modern Thyroid Cancer Pathology and ManagementJune 27th 2019
In an interview with <em>Targeted Oncology</em>, Andrew Turk, MD, discussed his presentation at the <em>3rd Annual</em> Congress on Oncology and Pathology as well as the current state of molecular testing for thyroid cancer and the future of testing and diagnostics.
KEYNOTE-189 Updates Show Improved Outcomes for Metastatic Nonsquamous NSCLCJune 26th 2019
In an interview with <em>Targeted Oncology, </em>Shirish Gadgeel, MBBS, of the Department of Medicine, Hematology/Oncology Division, University of Michigan, discussed recent study updates from the phase III KEYNOTE-189 trial and potential implications for the combination on clinical practice.
Biomarkers Being Identified for Improved Diagnosis of Nasopharyngeal Carcinoma Via Liquid BiopsyJune 21st 2019
During an interview with <em>Targeted Oncology</em>, lead study author Dhruvajyoti Roy, PhD, the director of technology at Laboratory for Advanced Medicine, Inc., shared information about the study, commented on other liquid biopsy research presented by peers at ASCO and provided insight as to what these data mean for the future of cell-free DNA methylation.
Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLCJune 19th 2019
Two abstracts presented at the 2019 ASCO Annual Meeting analyzed potential combinations with osimertinib (Tagrisso), a third-generation EGFR TKI, with additional agents to potentially overcome resistance mutations following progression in patients with <em>EGFR</em>-mutant NSCLC.
Study Explores Re-Treatment With PARP Inhibitors for Recurrent Ovarian CancerJune 12th 2019
One set of researchers are exploring the possibility of re-challenging patients with ovarian cancer with PARP inhibitors later in the course of treatment when their disease became recurrent. As the first to examine re-challenging patients with PARP inhibitors, researchers found that patients who had prior exposure to PARP inhibitors did not develop resistance and could, therefore, receive repeat treatment with PARP inhibitors.
Liquid Biopsies May Ease Genomic Evaluation and Disease Management for NSCLCJune 10th 2019
For detecting genetic drivers and molecular aberrations in patients with metastatic non–small cell lung cancer, performing biopsies with comprehensive cell-free DNA, or liquid biopsies, may be a viable substitute for tissue-based biopsies.